Physician profile
Jay Patel
NPI 1962841452
$52,313.11
in general payments reported to CMS, 2019-2025
28 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,309 · 2020: $15K · 2021: $21K · 2022: $12K · 2023: $1,205 · 2024: $1,022 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,357 · Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,356.84 |
| Food and Beverage | $1,060.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $43,125.42 | 2019-2022 | |
| Medacta USA, INC. | $5,285.33 | 2021-2024 | Gmk Sphere, Reverse Shoulder, Amistem |
| Fx Shoulder Solutions, INC | $1,798.43 | 2022 | |
| Microport Orthopedics INC | $597.80 | 2023 | Mpo Hip System |
| Ortho Development Corporation | $260.94 | 2024 | |
| Jazz Pharmaceuticals INC. | $206.84 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $177.12 | 2022-2023 | Oxford |
| Kuros Biosciences USA, INC | $170.36 | 2023 | |
| Stryker Corporation | $158.05 | 2025 | Flowtriever, Aequalis Ascend Flex |
| Idorsia Pharmaceuticals US INC | $83.84 | 2023-2024 | Quviviq |
| Abbott Laboratories | $64.60 | 2023 | Cardiomems |
| Incyte Corporation | $54.45 | 2019-2021 | |
| Daiichi Sankyo INC. | $43.26 | 2019 | |
| Depuy Synthes Sales INC. | $40.54 | 2023 | Healix Knotless Peek, Vapr |
| Vertex Pharmaceuticals Incorporated | $32.86 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $30.98 | 2020 | |
| Onkos Surgical, INC. | $23.13 | 2019 | |
| Puma Biotechnology, INC. | $22.84 | 2020 | |
| Amgen INC. | $18.69 | 2020 | |
| Horizon Therapeutics Plc | $18.27 | 2022 | |
| Shockwave Medical, INC | $17.97 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Taiho Oncology, INC. | $14.94 | 2019 | |
| Kyowa Kirin, INC. | $14.59 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.51 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $13.90 | 2024 | Zilretta, Iovera, Exparel |
| Astellas Pharma US INC | $11.88 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.57 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.